Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $610K fell 97.9% year over year, behind the -66.4% change in trailing-twelve-month revenue. Sequentially, it fell 80.2% from the prior quarter. Over 3 fiscal years it compounded at -31.1% a year.
Context
- Revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 8 analysts of $25.88M (-61.5%) for the fiscal year ending Dec 2026, a slowdown from the -51.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $610K-80.2% QoQ
- Last fiscal yearDec 2025
- $67.22M-51.4% YoY
- LTMMar 2026
- $45.35M-66.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -97.9% | -87.3% | +10.6 pp |
| 1 year | -51.4% | -61.5% | -10.1 pp |
| 3-year CAGR | -31.1% | -13.2% | +18.0 pp |
| 5-year CAGR | +37.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 67.22M USD
- Year-over-year change
- -51.4%
- 4-year CAGR
- +52.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.22M | -51.4% |
| FY2024 | 2024-12-31 | 138.39M | -12.3% |
| FY2023 | 2023-12-31 | 157.75M | -23.3% |
| FY2022 | 2022-12-31 | 205.76M | +1564.8% |
| FY2021 | 2021-12-31 | 12.36M | — |
Revenue vs competitors
How ARCT compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -66.4% is the 6th highest of 7, against a peer median of -22.6%.
- Over three fiscal years its annual growth of -31.1% compares with a peer median of -28.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $596.34M USD | -52.5% | -11.1% | |
| LTM Mar 2026 | $191.45M USD | +2889.9% | -28.8% | |
| LTM Mar 2026 | €156.33M EUR | -16.0% | -21.5% | |
| LTM Mar 2026 | $65.5M USD | +214.0% | -65.1% | |
| LTM Mar 2026 | $45.35M USD | -66.4% | -31.1% | |
| LTM Mar 2026 | €13.44M EUR | -29.2% | +62.0% | |
| LTM Mar 2026 | $921.49K USD | — | -68.4% | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | -81.5% | |
| Peer median (excluding ARCT) | — | -22.6% | -28.8% | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.36M | 205.76M | 157.75M | 138.39M | 67.22M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.03M |
| Gross Profit | 12.36M | 205.76M | 157.75M | 138.39M | 64.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.5% |
| Research & Development | 173.76M | 147.75M | 192.13M | 195.16M | 112.21M |
| Selling, General & Admin | 41.45M | 46.07M | 52.87M | 52.82M | 46.08M |
| Operating Expenses | 215.21M | 193.58M | 235.95M | 234.06M | 139.15M |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| EBITDA | (199.81M) | 15.17M | (24.17M) | (77.4M) | (62.76M) |
| EBITDA Margin | -1616.7% | 7.4% | -15.3% | -55.9% | -93.4% |
| Operating Income | (202.85M) | 12.18M | (78.21M) | (95.67M) | (74.96M) |
| Operating Margin | -1641.3% | 5.9% | -49.6% | -69.1% | -111.5% |
| Interest Income | 753K | 2.58M | 17.36M | 15.2M | 10.1M |
| Interest Expense | 2.67M | 3M | 767K | 0 | 0 |
| Other Income / Expenses | (822K) | (1.53M) | 50.32M | 14.72M | 9.17M |
| Income Before Tax | (203.67M) | 10.64M | (27.89M) | (80.95M) | (65.78M) |
| Pre-Tax Margin | -1648.0% | 5.2% | -17.7% | -58.5% | -97.9% |
| Income Tax Expense | 0 | 1.3M | 1.84M | (4K) | 0 |
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Net Margin | -1648.0% | 4.5% | -18.8% | -58.5% | -97.9% |
| EPS (Basic) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| EPS (Diluted) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| Weighted Avg Shares | 26.32M | 26.45M | 26.63M | 27M | 27.39M |
| Weighted Avg Shares (Diluted) | 26.32M | 27.09M | 26.63M | 27M | 27.39M |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.